Outcome and resource utilization of infants born with hypoplastic left heart syndrome in the Intermountain West

Shaji C Menon1, Heather T Keenan, Hsin-Yi Cindy Weng

  • 1Division of Pediatric Cardiology, University of Utah, Salt Lake City, Utah, USA. shaji.menon@utah.edu

Insights

Hypoplastic left heart syndrome (HLHS) in the Intermountain West shows a 14-year transplant-free survival of 33%. Despite improved surgical palliation, HLHS infants face high mortality and significant healthcare resource utilization.

Area of Science:

  • Pediatric Cardiology
  • Congenital Heart Disease
  • Public Health

Background:

  • Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect.
  • Outcomes and resource utilization for HLHS infants vary significantly.
  • Population-based data are crucial for understanding the true burden of HLHS.

Purpose of the Study:

  • To characterize the outcomes and resource utilization of all infants born with HLHS in the Intermountain West.
  • To analyze trends in survival and identify risk factors for mortality.
  • To assess lifetime hospitalization costs associated with HLHS management.

Main Methods:

  • Retrospective cohort study of 245 infants born with HLHS between January 1995 and January 2010.
  • Data divided into three eras (1995-1999, 2000-2004, 2005-2010) to assess temporal trends.
  • Cox proportional hazards regression used to analyze mortality; lifetime hospitalization days and charges were determined.

Main Results:

  • Overall 14-year transplant-free survival was 33%.
  • 1-year transplant-free survival in the most recent era (2005-2010) was 60% for the surgical cohort.
  • Risk factors for death included shock, chromosomal defects, and multiorgan dysfunction; improved survival associated with later birth era, higher birthweight, and gestational age.

Conclusions:

  • Population-based studies reveal persistent high mortality and resource utilization for HLHS, despite hospital-based improvements in survival after surgical palliation.
  • Factors such as shunt type, need for ECMO, renal dysfunction, and tricuspid valve regurgitation significantly impact post-stage 1 mortality.
  • Median cumulative lifetime hospitalization costs ranged from $201,812 to $296,213 depending on the stage of palliation.